摘要
目的统计奥氮平治疗精神分裂症的疗效和不良反应情况,对奥氮平疗效的影响因素进行分析,为临床合理用药提供依据。方法收集2018年12月至2019年4月西安市精神卫生中心使用奥氮平治疗的精神分裂症病人病例230例,对其基本信息(性别、年龄、治疗方案)、治疗前及治疗后1、2、3、4、6周的阳性和阴性症状量表(PANSS)评分和治疗6周后的副作用量表(TESS)评分进行统计分析。结果在持续治疗的6周后,痊愈病人29例(12.61%)、显著进步69例(30.00%)、好转87例(37.83%),总有效率达80.43%。治疗前、治疗后1、2、3、4、6周的PANSS评分差异有统计学意义;单一用药和联合用药疗效比较,不同性别病人的用药疗效比较,差异无统计学意义;不同年龄段病人的疗效比较,差异有统计学意义。25例病人出现不良反应现象,不良反应发生率为10.87%,不良反应发生率相对较低。结论奥氮平治疗精神分裂症起效快,疗效显著,不良反应发生率较低;联合用药不会提高奥氮平的治疗效果,反而会明显增加不良反应的发生率,因此临床上应遵循精神科“单一用药原则”,个体化给药,已达到合理用药的目的。
Objective To understand the efficacy and adverse reactions of Olanzapine in the treatment of schizophrenia and to guide rational use of Olanzapine in clinic.Methods A total of 230 cases of schizophrenic patients treated with Olanzapine in Xi'an Mental Health Center from December 2018 to April 2019 were collected.The basic information(gender,age,treatment plan),positive and negative syndrome scale(PANSS)scores before and 1,2,3,4 and 6 weeks after treatment of,treatment emergent symptom scale(TESS)scores 6 weeks after treatment were analyzed statistically.Results After six weeks of continuous treatment,29 cases(12.61%)were cured,69 cases(30.00%)were significantly improved,87 cases(37.83%)were improved,and the total effective rate was 80.43%.There were statistically significant differences in PANSS scores before and after treatment at 1,2,3,4 and 6 weeks.There was no signif‐icant difference in the efficacy of single drug and combined drug treatment,and there was no significant difference in the efficacy be‐tween genders.There were significant differences in the efficacy of different age groups.There were 25 cases of adverse reactions,the incidence of which was 10.87%and was relatively low.Conclusion Olanzapine is safe and reliable in the treatment of schizophrenia and can be widely used in clinic.Drug combination dose not improve the efficacy of Olanzapine,but significantly increases the inci‐dence of adverse reactions.So in clinical practice,the principle of"single drug use"and individualized drug administration should be followed to achieve the purpose of rational drug use.
作者
贾晓妮
高艺
陈建波
田玉梅
蔺华利
成昱霖
支媗
张晓红
JIA Xiaoni;GAO Yi;CHEN Jianbo;TIANYumei;LIN Huali;CHENG Yulin;ZHI Xuan;ZHANG Xiaohong(Department of Science and Education,Xi'an Mental Health Center,Shaanxi,Xi'an 710100,China;Department of Pharmacy,Xi'an Mental Health Center,Shaanxi,Xi'an 710100,China;Department of Women's Men-tal Health,Xi'an Mental Health Center,Shaanxi,Xi'an 710100,China;Department of Pharmacy,Shaanxi Provincial Hospital of Tuberculosis Prevention and Treat-ment,Shaanxi,Xi'an 710100,China)
出处
《安徽医药》
CAS
2021年第11期2317-2320,共4页
Anhui Medical and Pharmaceutical Journal
基金
西安市科技计划项目[201805099YX7SF33(3)、201805099YX7SF33(4)]
西安市卫生健康委员会科研项目(J201801004)。
关键词
精神分裂症
奥氮平
临床疗效
影响因素
Schizophrenia
Olanzapine
Clinical efficacy
Influencing factors
